Predictors of new malignant ventricular arrhythmias after coronary surgery A case-control study by Ascione, Raimondo et al.
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OBJECTIVES We sought to investigate the relationship between perioperative factors and the occurrence of
ventricular tachycardia (VT) and ventricular fibrillation (VF), as well as the impact of VT/VF
on early and late mortality.
BACKGROUND Both VT and VF are rare but serious complications after coronary artery bypass graft surgery
(CABG), and their etiology and implications remain uncertain.
METHODS Data on 4,411 consecutive patients undergoing CABG (1,154 [25.8%] had off-pump surgery)
between April 1996 and September 2001 were extracted from a prospective database and
analyzed. Odds ratios (ORs) describing associations between possible risk factors and VT/VF
were estimated separately. Factors observed to be significantly associated with VT/VF were
further investigated using multivariate logistic regression.
RESULTS Sixty-nine patients suffered VT/VF (1.6%). There were 61 (1.4%) in-hospital/30-day deaths,
15 among patients who had postoperative VT/VF (21.7%). Patient factors independently
associated with an increase in the odds of VT/VF included age 65 years, female gender,
body mass index 25 kg/m2, unstable angina, moderate or poor ejection fraction, and the
need for inotropes and an intra-aortic balloon pump (OR 1.72 to 4.47, p  0.05). After
adjustment, off-pump surgery was associated with a substantial but nonsignificant protective
effect against VT/VF (OR 0.53, 95% confidence interval [CI] 0.25 to 1.13; p  0.10).
Actuarial survival at two years was 98.2% among patients who had VT/VF and who survived
to discharge/30 days, compared with 97.0% for the control group (adjusted hazard ratio 0.96
(95% CI 0.40 to 2.31, p  0.92).
CONCLUSIONS The incidence of VT/VF is low in patients undergoing coronary surgery but is associated with
high in-hospital mortality. The late survival of the discharged VT/VF patients compares
favorably with that of controls. (J Am Coll Cardiol 2004;43:1630–8) © 2004 by the
American College of Cardiology Foundationt
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gustained ventricular tachycardia (VT) and ventricular fi-
rillation (VF) are life-threatening complications (1,2).
any cardiac diseases may increase the risk of ventricular
rrhythmias, but acute ischemia and previous myocardial
nfarctions (MIs) are by far the most common (1). New
entricular arrhythmias may also be observed after coronary
rtery bypass graft surgery (CABG), varying from ventric-
lar ectopy (3) to tachyarrhythmias such as nonsustained
T, sustained VT, and VF (1–3). Patient and operative
actors, inadequate myocardial protection, metabolic imbal-
nce, residual ischemia, and surgical factors like incomplete
evascularization and suboptimal anastomosis are all poten-
ial causes of VT/VF during the recovery period after
ABG (1–4). In addition to the importance of the clinical
onsequences of VT/VF, these complications may have an
conomic effect by prolonging the intensive care unit and
ospital stay. Evidence in the literature describing the
requency of new VT/VF in the recovery period after
ABG remains anecdotal (5–7), and the lack of informa-
From the Bristol Heart Institute, Bristol Royal Infirmary, Bristol, United King-
om. The Garfield Weston Trust and the British Heart Foundation supported this
ork.
Manuscript received May 2, 2003; revised manuscript received October 20, 2003,2ccepted November 3, 2003.ion on possible risk factors for VT/VF is alarming in view
f the life-threatening nature of this complication.
The aims of this study were two-fold: first, to investigate
ssociations between patient and operative factors and the
ccurrence of VT/VF; second, to describe the impact of
T/VF on early and late mortality in a large population
ndergoing myocardial revascularization.
ETHODS
atient selection. A nested case-control study was carried
ut using data collected prospectively from an unselected
ohort of patients undergoing CABG. By defining the
roups to be compared on the basis of the outcome of
nterest, this study design can investigate a wide range of
actors that may be associated with a rare outcome. The
epresentative nature of the cohort meant that the incidence
f VT/VF could also be estimated. All data were collected
rospectively at the time of operation and entered into the
atient Activity Tracking System (PATS) database (Den-
rite Systems, London, United Kingdom), which is main-
ained routinely in our institution to document cardiac
urgical activity. The analysis included all patients under-
oing CABG between April 1, 1996, and September 13,
001, with no previous history of VT/VF. During the study
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May 5, 2004:1630–8 Ventricular Arrhythmias During Coronary Surgeryeriod, surgeons in our institution began to carry out
ff-pump CABG and have used this new technique with
ncreasing frequency, as well as in a wider range of patients,
s they have gained more experience. Data were included for
ll CABG patients, irrespective of whether they underwent
onventional CABG or off-pump CABG.
Cases were defined as patients who required advanced
ardiac life support interventions to terminate the malignant
rrhythmia and to stabilize the patient in the postoperative
eriod before discharge. Controls were defined as all other
atients in the cohort. The prevalence of preoperative
haracteristics, surgical factors, and aspects of postoperative
anagement were compared between cases and controls.
nesthetic and surgical technique. Anesthetic and surgi-
al techniques were standardized for all patients and have
een previously reported (8).
For patients undergoing on-pump CABG, cardiopulmo-
ary bypass was instituted using ascending aortic cannula-
ion and two-stage venous cannulation of the right atrium.
on-pulsatile flow was used, and flow rates throughout
ypass were 2.4 l/m2/min. A systemic temperature was kept
etween 34°C and 36°C. Myocardial protection was
chieved by using intermittent anterograde hyperkalemic
arm-blood cardioplegia (8). For patients undergoing off-
ump CABG, the target vessel was exposed and snared
bove the anastomotic site using a 4-0 prolene suture with
soft plastic snugger. The coronary artery was then opened;
n intracoronary shunt was used in case of relative electro-
ardiographic (ECG) or hemodynamic instability or exces-
ive bleeding; and the anastomosis was performed using a
ressure stabilizer (9).
ostoperative management. At the end of surgery, pa-
ients were transferred to the intensive care unit. Forced air
arming was used until a stable nasopharyngeal temperature
f 37°C had been reached. Patients were extubated as soon
s they met the following criteria: hemodynamic stability,
o excessive bleeding (80 ml/h), normothermia, and
onsciousness with pain control. Fluid management post-
peratively consisted of 5% dextrose infused at 1 ml/kg/h,
ith additional Gelofusine or blood to maintain normovol-
Abbreviations and Acronyms
BMI  body mass index
CABG  coronary artery bypass graft surgery
CI  confidence interval
EF  ejection fraction
IABP  intra-aortic balloon pump
ICD  implantable cardioverter-defibrillator
LV  left ventricular
MI  myocardial infarction
OR  odds ratio
PATS  Patient Activity Tracking System
VF  ventricular fibrillation
VT  ventricular tachycardiamia and a hematocrit level 24%. Potassium and magne- sium deficiency was promptly treated, as necessary, to
aintain electrolyte balance within the normal range.
linical data collection, monitoring, and definitions. A
ide range of potential risk factors for VT/VF (Table 1),
ncluding preoperative interventions indicative of low car-
iac output (i.e., requirement for intra-aortic balloon pump
IABP] or inotropic support [5 g/kg/min of dopamine]
or 30 min to maintain systolic blood pressure 90 mm
g and a cardiac index 2.2 l/min/m2), and intraoperative
nd postoperative data were entered prospectively into the
ATS data base. According to our unit protocol, blood
ressure and heart rate and rhythm were continuously
onitored and displayed on a screen inclusive of an auto-
ated arrhythmia detector (Solar 8000 Patient Monitor,
arquette Medical Systems, Milwaukee, Wisconsin) dur-
ng the first 72 h postoperatively. Automatic printing of the
CG was related to the predefined alarm levels. Twelve-
ead ECG recordings were obtained preoperatively, 2 h
ostoperatively, and then daily thereafter until discharge.
Each episode of arrhythmia was printed out and inter-
reted by an intensivist. Sustained VT was defined as a
niform tachyarrhythmia of ventricular origin that had a
uration of 20 s, unless terminated earlier because of
emodynamic collapse. When VT/VF occurred, standard
dvanced cardiac life support was commenced to terminate
he arrhythmia and to stabilize the patient. Ventricular
achycardia was managed according to standard protocols of
ur unit. These protocols aim to achieve assessment and
reatment of any acute reversible or correctable cause of
rrhythmia, including metabolic alterations, myocardial
schemia/infarction, congestive heart failure, and potentially
roarrhythmic medications. Patients who had an isolated
pisode of in-hospital VT/VF are discharged with antiar-
hythmic medications for a period of at least six months,
ccording to the outcome of follow-up in the cardiology
utpatient clinic. Patients with more than one episode of
T/VF are referred to a cardiologist for an electrophysi-
logic study to assess the need for an implantable
ardioverter-defibrillator (ICD).
ample size. Even with over 4,000 patients (Table 1), the
ower of the analysis was limited because of the rarity of
T/VF (1.6%). The power of the analyses to detect clini-
ally important associations depended on both the preva-
ence of the risk factor among controls and the magnitude of
he risk conferred, as well as the incidence of VT/VF. The
nalyses had 80% power to detect an odds ratio (OR) of
3.3 for risk factors with a prevalence of 5% at a 5%
two-tailed) significance level, or an OR of 2.2 for risk
actors with a prevalence of20%. Risk factors with an OR
f 2.0 were unlikely to be detected by the analyses.
tatistical analysis. We chose not to include deaths in a
omposite outcome measure, because the occurrence of
T/VF is almost always identified clinically before death.
herefore, it would have been inappropriate to pool patients
ho died two or more days after the operation, havinghown no early signs of VT/VF, with patients in whom
1632 Ascione et al. JACC Vol. 43, No. 9, 2004
Ventricular Arrhythmias During Coronary Surgery May 5, 2004:1630–8Table 1. Prevalence of Potential Risk Factors Among Cases and Controls
VT/VF Group (n  69) Control Group (n  4,342)
n (%)* n (%)*
Preoperative factors
Age at operation (yrs)
16 and 55 12 (17.4) 747 (17.2)
55 and 65 26 (37.7) 1,462 (33.7)
65 and 75 22 (31.9) 1,756 (40.4)
75 9 (13.0) 377 (8.7)
Male gender 45 (65.2) 3,531 (81.3)
Body mass index (kg/m2)
20 4 (6.1) 129 (3.0)
20 and 25 25 (37.9) 1,129 (26.5)
25 and 30 27 (40.9) 2,122 (49.8)
30 and 35 9 (13.6) 730 (17.1)
35 1 (1.5) 154 (3.6)
CCS class
0/1 14 (20.2) 1,627 (37.5)
2 28 (40.6) 1,479 (34.1)
3 27 (39.1) 1,228 (28.3)
NYHA functional class
I 6 (8.7) 932 (21.5)
II 24 (34.8) 1,882 (43.4)
III 29 (42.0) 1,298 (29.9)
IV 10 (14.5) 223 (5.1)
Unstable angina 47 (68.1) 1,834 (42.4)
Current congestive heart failure 8 (2.8) 120 (11.6)
Previous myocardial infarction 32 (46.4) 1,913 (44.2)
Diabetes 14 (13.9) 799 (14.4)
Hypercholesterolemia 58 (57.4) 3,422 (61.7)
Hypertension 50 (49.5) 2,968 (53.4)
Current smoker 17 (16.8) 653 (11.7)
Previous cerebrovascular accident 10 (9.9) 444 (8.0)
Pre-existing respiratory disease 7 (6.9) 554 (10.0)
Previous/preoperative arrhythmia 12 (11.9) 501 (9.0)
Preoperative atrial fibrillation 5 (5.8) 146 (3.4)
Left main stenosis 50% 12 (15.6) 570 (12.4)
Intra-aortic balloon pump 5 (7.3) 21 (0.5)
Inotropic support 51 (73.9) 1,729 (39.9)
Severity of coronary disease
Single-vessel 4 (6.0) 319 (7.5)
Double-vessel 12 (17.9) 1,062 (24.8)
Triple-vessel 51 (76.1) 2,895 (67.7)
Preoperative ejection fraction
Good (50%) 34 (49.3) 3,095 (71.9)
Fair (30–50%) 25 (36.2) 992 (23.0)
Poor (30%) 10 (14.5) 220 (5.1)
Operative priority
Elective 20 (29.0) 1,966 (45.3)
Urgent 43 (62.3) 1,797 (41.4)
Emergency/salvage 6 (8.7) 574 (13.2)
Parsonnet score
0–10 42 (60.9) 3472 (80.0)
11–20 21 (30.4) 781 (18.0)
20 6 (8.7) 88 (2.0)
Surgical factors
Off-pump CABG 12 (17.4) 1,123 (25.9)
Number of grafts
1 6 (8.7) 348 (8.0)
2 17 (24.6) 1,157 (26.7)
3 35 (50.7) 2,020 (46.5)
4 11 (15.9) 815 (18.8)
*Denominators were not always 69 and 4,342, respectively, because some variables were missing for a small number of patients (see
text).
CABG coronary artery bypass graft surgery; CCSCanadian Cardiovascular Society; NYHANew York Heart Association;
VT/VF  ventricular tachycardia/ventricular fibrillation.
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May 5, 2004:1630–8 Ventricular Arrhythmias During Coronary SurgeryT/VF was clinically manifested. Patients who died in the
ospital were therefore included in case or control groups on
he same basis as patients who survived (i.e., according to
hether or not they showed signs in the immediate peri-
perative and postoperative period of having experienced
T/VF.
More variables are available in the PATS database than
re described here. A decision about the key variables of
nterest to investigate was made before conducting any
nalyses. All variables selected at the outset of investigation
re listed in Table 1. Some continuous variables were
rouped for analysis. Age, body mass index (BMI), Parson-
et score, and ejection fraction (EF) were dichotomized
65 vs. 65 years, BMI 25 vs. 25 kg/m2, Parsonnet
core 10 vs. 10, and good vs. moderate or poor EF,
espectively) for the multivariate analyses for ease of inter-
retation and because ORs in the multivariate models for
djacent categories were similar.
All analyses were carried out by logistic regression mod-
ling, adjusting the standard errors of estimates of ORs for
lustering of patients within consultant teams. Multivariate
nalyses considered all predictors that separately showed any
vidence of an association with VT/VF (p  0.20). Predic-
ors were retained in the final “adjusted” model if they were
ndependently associated with the occurrence of VT/VF (p
0.05). When two or more predictors were strongly
orrelated, only one factor (the one that was most strongly
ssociated with VT/VF) was retained in the final model.
The risk of postoperative VT/VF for subsequent mortal-
ty was then investigated by survival analysis, first, consid-
ring all deaths, and second, only the deaths that occurred
fter hospital discharge. For the latter analysis, the same
time zero” was used (i.e., date of operation), but the
nalysis was confined to patients who survived 30 days or to
ospital discharge, if the discharge occurred more than 30
ays after the operation. Univariate and multivariate Cox
egression models were fitted, stratified by consultant team,
o estimate survival at one and three years and the hazard
atio for the group that had experienced VT/VF.
A post hoc subgroup analysis was carried out among
atients who suffered VT/VF, comparing patients who had
T/VF intraoperatively or postoperatively, to ascertain
hether the time of occurrence was influenced by patient
actors. The latter group was further classified according to
he time of postoperative occurrence of VT/VF (i.e., 24 h
ostoperatively).
All analyses were carried out using STATA version 7
STATA Corp., Houston, Texas).
ESULTS
escription of study population. During the study pe-
iod, a total of 4,467 patients underwent CABG, of whom
,154 (25.8%) had off-pump surgery. Information on
hether or not VT/VF had occurred was missing for 56
atients (1.3%; these patients are not considered further), mut data on potential risk factors were complete for more
han 99% of the remaining 4,411 cases for 23 of the 25
reoperative patient factors investigated. Exceptions were
MI (4,330 of 4,411 [98.2%]) and severity of coronary
isease (4,270 of 4,411 [98.5%]). Sixty-nine of the 4,411
atients (1.6%; 95% confidence interval [CI] 1.2% to 2.0%)
ad new-onset VT/VF, all as an isolated episode. Overall,
here were 61 deaths in the hospital or deaths within 30 days
f CABG (1.4%), 15 among the 69 patients who had
T/VF (21.7%). These 15 patients died zero to 43 days
fter the operation. The intraoperative occurrence of
T/VF had a stronger impact on mortality (5 of 12
41.6%]), as compared with postoperative VT/VF (10 of 57
17.5%]).
redictors of VT/VF. Several preoperative factors were
eparately associated with a significant increase in the odds
f VT/VF (p  0.05; ORs ranging from 2.21 to 17.3)
Table 2), including female gender, Canadian Cardiovascu-
ar Society classification, New York Heart Association
unctional class, presence of unstable angina, congestive
ardiac failure, preoperative use of IABP, preoperative use
f inotropes, Parsonnet score, decreasing preoperative EF,
nd operative priority. An increasing BMI appeared to be
rotective against VT/VF (OR 0.57, p 0.05 for BMI25
nd 30 kg/m2 vs. 20 and 25 kg/m2) (Table 2). There
as no evidence that atrial fibrillation before the index
peration was more or less likely in patients who experi-
nced VT/VF than in patients who did not.
Multiple logistic regression modeling identified eight
reoperative factors that were independently associated with
he risk of any VT/VF (Table 2): age 65 years, female
ender, BMI 25 kg/m2, preoperative unstable angina,
ABP required, inotropes required, Parsonnet score 10,
nd poor or moderate EF. The ORs for these risk factors
anged from 1.72 (moderate or poor EF) to 4.47 (preoper-
tive requirement for IABP).
Operative risk factors (off-pump surgery and number of
rafts) were added to the adjusted model containing preop-
rative predictors. Off-pump surgery was associated with a
ubstantial but nonsignificant protective effect against
T/VF (OR 0.53, 95% CI 0.25 to 1.13; p  0.10). The
umber of grafts carried out did not appear to be an
mportant risk factor for VT/VF. The ORs for all preoper-
tive variables were essentially unchanged when operative
actors were added to the multivariate model.
We also investigated associations between the occurrence
f VT/VF and postoperative in-hospital outcome. Periop-
rative MI and atrial fibrillation were much more common
n patients who had VT/VF than in patients who did not
MI: 14.5% vs. 1.7%; atrial fibrillation: 36.2% vs. 11.5%,
oth p  0.0001). These associations were observed irre-
pective of whether VT/VF occurred in the first 12 hours
fter the operation or subsequently. Unfortunately, the
atabase did not include more detailed information on the
elative timing of the events. Patients who had VT/VF were
ore likely to have other serious complications as well (e.g.,
1634 Ascione et al. JACC Vol. 43, No. 9, 2004
Ventricular Arrhythmias During Coronary Surgery May 5, 2004:1630–8Table 2. Unadjusted and Adjusted Odds Ratios for Ventricular Tachycardia/Fibrillation
OR
Unadjusted*
95% CI p Value OR
Adjusted†
95% CI p Value
Preoperative factors
Age at operation (yrs)
16 and 55 1.29 0.64–2.63
55 and 65 1.42 0.80–2.52
65 and 75 1.00 —
75 2.01 0.92–4.41
65‡ 2.38 1.33–4.28 0.004
Female gender 2.33 1.41–3.85 0.001 2.40 1.38–4.15 0.002
Body mass index (kg/m2)
20 1.49 0.51–4.37 0.47
20 and 25 1.00 — —
25 and 30 0.57 0.33–0.99 0.05
30 0.50 0.24–1.05 0.07
25‡ 1.73 1.02–2.92 0.04
CCS class — — —
0–2 1.00 — —
3 2.22 1.16–4.23 0.02
4 2.55 1.33–4.89 0.005
NYHA functional class — — —
I 1.00 — —
II 2.00 0.82–4.92 0.13
III 3.49 1.44–8.46 0.006
IV 6.75 2.42–18.8 0.001
Unstable angina 2.89 1.73–4.81 0.001 1.95 1.14–3.34 0.02
Current congestive heart failure 4.61 2.15–9.89 0.001 — — —
Previous Q-wave myocardial infarction 1.07 0.67–1.73 0.77 — — —
Diabetes 0.77 0.38–1.56 0.47 — — —
Hypercholesterolemia 1.40 0.79–2.50 0.25 — — —
Hypertension 0.98 0.60–1.58 0.92 — — —
Current smoker 1.66 0.90–3.07 0.10 — — —
Previous cerebrovascular accident 1.69 0.83–3.44 0.15 — — —
Pre-existing respiratory disease 1.04 0.47–2.30 0.92 — — —
Preoperative arryhthmia 1.37 0.49–3.80 0.55 — — —
Left main stem stenosis 50% 1.48 0.79–2.78 0.23 — — —
Intra-aortic balloon pump 17.3 6.23–48.1 0.001 4.47 1.29–15.5 0.02
Inotropic support 4.26 2.48–7.32 0.001 3.14 1.78–5.54 0.001
Parsonnet score — — —
0–10 1.00 — —
11–20 2.30 1.36–3.92 0.002
20 5.74 2.37–13.9 0.001
10‡ 1.95 1.04–3.66 0.04
Severity of coronary disease — — —
Single vessel 1.00 — —
Double vessel 0.85 0.27–2.65 0.78
Triple vessel 1.46 0.52–4.07 0.47
Preoperative ejection fraction
0 1.00 — —
1 2.21 1.31–3.73 0.003
2 3.87 1.88–7.97 0.001
Moderate/poor‡ 1.72 1.02–2.92 0.04
Operative priority (101/5,567) — — —
Elective 1.00 — —
Urgent 2.33 1.36–3.99 0.002
Emergency/salvage 1.08 0.43–2.72 0.87
*Unadjusted analyses took into account the consultant team carrying out the operation but did not adjust for any preoperative
or operative risk factors. †Adjusted analyses took into account the consultant team carrying out the operation and all other
preoperative risk factors for which odds ratio estimates are described (i.e., age 65 years, female gender, body mass index 25
kg/m2, presence of unstable angina, requirement for preoperative intra-aortic balloon pump or use of inotropes, moderate or poor
ejection fraction). ‡Risk factor was dichotomized in multivariate analyses to make interpretation of the model easier and because
odds ratios for adjacent categories were similar.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.
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May 5, 2004:1630–8 Ventricular Arrhythmias During Coronary Surgeryequiring inotropes, hemodialysis, or reintubation or having
ransient stroke or multiorgan failure). As with perioperative
I and atrial fibrillation, we were unable to identify
hether these other complications preceded or followed
T/VF.
nalysis of VT/VF group. The timing of the malignant
rrhythmias was either at anesthetic induction or during the
peration in 12 patients (17.5%) and postoperatively in the
emaining 57 (85.6%). Five (42%) of 12 patients who
xperienced intraoperative VT/VF died in the hospital, as
ompared with 10 (18%) of 55 patients who had VT/VF on
he intensive care unit or ward (p  0.08) (data on timing
f VT/VF were missing for 2 patients). Of the 15 in-
ospital deaths within the VT/VF group, two died within
he first 3 h postoperatively. The remaining 13 patients died
etween postoperative days 2 and 43. Among the 57
atients with postoperative VT/VF, 27 (47.4%) had the
vent within the first 24 h.
A subgroup analysis was carried out between patients
ith VT/VF either intraoperatively or postoperatively to
scertain whether this time of occurrence was influenced by
aseline status (i.e., recent MI, poor left ventricular [LV]
unction, emergency referral). The comparison between the
wo subgroups did not show any significant associations
etween VT/VF and baseline recent MI, poor LV function,
r emergency referral, with p values of 0.74, 0.42, and 0.11,
espectively. Of the 54 VT/VF patients surviving to dis-
harge or 30 days, 29 (53.7%) were discharged while
eceiving amiodarone, 15 (27.7%) beta-blockers, and 10
18.5%) both. None of the VT/VF patients underwent ICD
lacement.
ate clinical outcome in VT/VF patients. The overall
edian duration of follow-up was 3.6 years (interquartile
ange 2.2 to 4.9 years). The duration of follow-up differed
or case and control groups (2.8 vs. 3.6 years, respectively),
ut only because of the deaths in the hospital or within 30
ays. Among survivors to discharge/30 days, the median
ollow-up was 3.6 years in both groups. In total, there were
32 deaths during follow-up (i.e., there were a further 271
eaths in addition to the 61 that occurred in the hospital or
ithin 30 days). Actuarial survival for patients who had
n-hospital VT/VF and who survived to discharge/30 days
as 76.8% at 2 years, compared with 96.0% for the control
roup (unadjusted hazard ratio 4.54, 95% CI 3.39 to 6.07;
 0.0001). Independent preoperative risk factors for
id-term mortality included younger age, diabetes, unstable
ngina, congestive cardiac failure, poor EF, hypertension,
revious cerebrovascular accident, preexisting respiratory
omorbidity, requirement for inotropes, and increasing Par-
onnet score. After adjusting for these risk factors, the
azard ratio was 3.52 (95% CI 2.13 to 5.81, p  0.0001).
The Kaplan-Meier curve for this analysis suggested that
xcess mortality in the VT/VF group occurred only during
he immediate postoperative period (Fig. 1). The analysis
as therefore rerun including only those patients whourvived to discharge and who survived beyond 30 days. The aurvival estimates are imprecise for this analysis because the
otal number of patients who experienced VT/VF and
urvived to discharge and beyond 30 days was small (n 
4), and there were only four deaths during follow-up in
his group (vs. 267 deaths after discharge and beyond 30
ays in the control group). Survival for patients who had
n-hospital VT/VF was 98.2% at two years, compared with
7.0% for the control group (unadjusted hazard ratio 1.13,
5% CI 0.55 to 2.34; p  0.74). Independent preoperative
isk factors for mid-term survival after hospital discharge
ncluded unstable angina, congestive cardiac failure, mod-
rate and poor EF, previous cerebrovascular accident, re-
uirement for inotropes, increasing Parsonnet score, and
perative priority. After adjusting for these risk factors, the
azard ratio was 0.92 (95% CI 0.43 to 1.99, p  0.83).
ISCUSSION
ew occurrences of VT/VF may affect the recovery period
fter CABG. Despite its life-threatening nature, there are
ew studies in the literature addressing this topic (5–7).
onsequently, associations between patient and operative
actors and the occurrence of VT/VF, as well as its impact
n early and late mortality, remain uncertain. This is the
rst large study based on prospectively collected data to
nvestigate the new onset of VT/VF after coronary surgery.
The observed incidence of sustained VT/VF in the
resent cohort was 1.6%, considerably less than previously
eported. Steinberg et al. (10) reported an incidence of 3.1%
f in-hospital sustained VT/VF after CABG at a single
nstitution in a population of 382 consecutive patients. A
imilar or higher incidence has been reported by others
3,5,11). A potential explanation might be the use, at our
nstitution, of intermittent anterograde warm-blood cardio-
legia, which is known to reduce the occurrence of ventric-
lar arrhythmias and the need for administration of lido-
aine hydrochloride for treatment of ventricular arrhythmias
igure 1. Kaplan-Meier survival estimates: all deaths (dashed line 
entricular tachycardia (VT)/ventricular fibrillation (VF) cases; solid line
controls). CI  confidence intervalfter CABG (12). The use of off-pump coronary surgery in
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ted, as the use of this technique was observed to have a
ubstantial protective effect against VT/VF, although this
id not reach significance.
The present study identifies several independent predic-
ors of new-onset, sustained VT/VF in patients undergoing
oronary surgery. It is tempting to consider whether these
isk factors can help to clarify the clinical profile of high-risk
atients, perhaps allowing a preoperative risk stratification
ethod for VT/VF, with the possibility of prescribing a
rophylactic regimen for those at highest risk. Unfortu-
ately, the risk factors for VT/VF that we observed do not
elp very much to identify a subgroup of patients at high
isk of VT/VF. Formally, the area under the receiver-
perating characteristics curve for the model was 0.78.
aximizing the proportion of patients correctly classified by
he model (98.5%) yielded a sensitivity of only 1.5%; on the
ther hand, setting an acceptable sensitivity (i.e., 70%)
ielded a specificity of only 71% (the statistics overestimate
he performance of the model since they are calculated from
he same dataset on which the model was estimated).
The poor prediction of individual patients arises from the
arity of VT/VF and the fact that the majority of the risk
actors were common; age 65 years, female, BMI 25
g/m2, unstable angina, and moderate or poor EF had
revalences of over 20% in the study population. Patients
ho needed preoperative inotropic support or an IABP
ere less frequent, and these risk factors were associated
ith higher ORs. Therefore, it may be reasonable to regard
hese patients as being at high risk of VT/VF, but these
actors alone have only about half the predictive power than
ll of the predictors. If it is subsequently shown that
ostoperative atrial fibrillation usually precedes VT/VF, this
ould also be an important, albeit postoperative, risk factor
or VT/VF.
Our study strongly suggests that patients who had
T/VF were more likely to die in the hospital (21.7%), as
ompared with patients who did not (1.0%). This finding is
onsistent with the 25% in-hospital mortality rate reported
y Steinberg et al. (10). Of interest is that intraoperative
ccurrence of VT/VF had a stronger impact on in-hospital
ortality than did postoperative VT/VF.
The presence of baseline unstable angina was found to be
n independent predictor of the occurrence of VT/VF. The
xtent of coronary disease, time of cardioplegic arrest,
ardioplegic solution, route of delivery, and temperature of
he perfusate may all contribute to nonhomogeneous myo-
ardial protection (13), triggering many potential patho-
hysiologic mechanisms of ventricular arrhythmias in un-
table angina patients. Unstable angina-induced ischemia
ay indeed determine alterations in cellular electrophysiol-
gy, local accumulation of catecholamines, abnormal auto-
aticity within surviving Purkinje fibers, or reentry within
he ischemic myocardium (14). Steinberg et al. (10) re-
orted that grafting a non-collateralized, totally occluded
essel supplying an infarct zone is independently associated aith the occurrence of VT. They hypothesized that resump-
ion of blood flow to areas previously poorly perfused could
otentially restore electrophysiologic function to cells em-
edded within the borders of myocardial scar and create
e-entrant circuits.
In contrast to other reports, a history of MI was not
ssociated with occurrence of VT/VF in our study (15,16).
his might be due to the fact that most of our pre-infarcted
atients were operated on at least one to two weeks after
cute MI. Cheema et al. (14) have highlighted the poor
rognostic significance of VT occurring in the setting of
cute MI (within the first days), as opposed to a negative
rognostic outcome, as suggested by Bigger et al. (17), when
ccurring in the setting of healing MI (more than seven days
fter MI).
We also found a significant association between moderate
o poor LV function and the occurrence of VT/VF. The
resence of impaired LV function is not synonymous with
rreversible damage, as hibernated or stunned myocardium
ay also contribute to poor LV function (18). Steinberg et
l. (10) suggested the importance of not only coronary
erfusion to maintain the electrical viability of critical
rrhythmogenic tissue but also a reversible state of “electrical
ibernation,” which may only be possible in the absence of
rreversible myocardial injury. Our findings seem to support
his hypothesis. Others, however, have demonstrated the
ssociation between revascularization of an area of previous
I and the development of sustained VT/VF (19).
Another interesting finding of the present study was the
ignificant association between female gender and VT/VF
fter coronary surgery. The gender-specific electrophysi-
logic structure of the heart and/or hormonal effects on
odulation ionic channel function may help to explain
ifferences such as the increased prevalence of symptoms of
ongenital long QT syndrome in women and the increase in
pisodes of supraventricular tachycardia in the perimen-
trual period (20,21). This seems to be supported also by
xperimental data. Saba et al. (22) found that in female
ice, estrogen prolongs atrioventricular nodal conduction
nd the right ventricular effective refractory period. In
ontrast, Aronson and Burger (23) found that complex
entricular ectopy and episodes of ventricular tachycardia
re significantly lower in women. However, this was not a
urgical series; therefore, patients were not exposed to all of
he potential triggering factors that act exclusively as a
onsequence of surgery.
We identified age65 years as an independent risk factor
or VT/VF and overweight/obesity (25 kg/m2) as a
rotective factor. These findings are quite interesting, as no
imilar results are reported in the literature. Limited devel-
pment of collaterals in younger patients with severe coro-
ary disease might make these patients less tolerant to
schemia, which, in turn, might trigger the occurrence of
T/VF.
Patients with in-hospital VT/VF and discharged homeppear to have a late survival comparable to the controls.
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May 5, 2004:1630–8 Ventricular Arrhythmias During Coronary Surgeryhere are several potential explanations for this finding.
irst, all of the VT/VF patients were discharged on antiar-
hythmic drugs (i.e., amiodarone [53.7%], beta-blockers
27.7%], or both [18.5%]). A recent meta-analysis of 13
andomized trials using amiodarone reported a 13% overall
eduction in total mortality and a 29% reduction in antiar-
hythmic death (24). Others have highlighted the role of
eta-blockers in improving survival in VT/VF patients (25).
t has also been suggested, however, that a favorable
esponse to antiarrhythmic therapy simply identifies a lower
isk population, and no direct benefit is gained by treatment
ith antiarrhythmic drugs (26). This could be true in our
eries, as all patients underwent revascularization, which
ould have removed the electrical milieu responsible for
uture arrhythmic events. Furthermore, a postoperative
etabolic or electrolyte imbalance was promptly treated
ith definitive removal of a further potential triggering
actor of VT/VF. These results also support our policy of
ot implanting an ICD in patients with an isolated episode
f VT/VF.
Case-control studies are susceptible to bias and con-
ounding (27), and it is important to consider the extent to
hich these problems may have affected our findings. We
hink that confounding from a selection bias is an unlikely
xplanation for the findings observed in this study, because
ases and controls were drawn from exactly the same
opulation, an advantage of the “nested” design. However,
e cannot rule out the possibility of incomplete adjustment
or confounding in the multivariate analyses. The prospec-
ive nature of data collection also protects against bias, as the
ase or control status of participants could not have influ-
nced the measurement of outcome or predictor factors.
ias could also have arisen from missing data, especially
ith respect to missing data for the occurrence of VT/VF.
owever, our use of an automated system for detection of
rrhythmias makes this very unlikely.
tudy limitations. One of the limitations of the present
tudy is that despite the large size of the cohort, it could only
dentify factors that conferred a substantial increase in risk
ecause of the rarity of VT/VF. Other factors that were not
ound to be significantly associated with VT/VF from a
tatistical perspective may nevertheless confer a clinically
mportant increase in risk (e.g., congestive cardiac failure
nd MI). These potential predictors of VT/VF need to be
nvestigated further in larger cohorts. Also, we cannot rule
ut the possibility that we missed late, self-converting,
onsustained episodes of VT/VF in our study. However,
his is unlikely for the first 72 h postoperatively due to
ontinuous monitoring with an automated arrhythmia de-
ector. Furthermore, nonsustained VT/VF was not part of
he primary outcome of the present study.
onclusions. This study shows a relatively low incidence
f VT/VF in patients undergoing coronary surgery, but
here was a high in-hospital mortality associated with this
omplication. In contrast, the late survival of discharged
T/VF patients compares favorably with that of controls. 2everal factors were found to be independently associated
ith the occurrence of VT/VF. Knowledge of important
isk factors for VT/VF may be useful in order to optimize
patient’s preoperative physiologic status, the surgical
echniques used, and perioperative and postoperative
anagement.
eprint requests and correspondence: Dr. Raimondo Ascione,
ristol Heart Institute, Bristol Royal Infirmary, Bristol BS2 8HW,
nited Kingdom. E-mail: R.Ascione@bristol.ac.uk.
EFERENCES
1. Welch PJ, Page RL, Hamdan MH. Management of ventricular
arrhythmias. J Am Coll Cardiol 1999;34:621–30.
2. O’Rourke RA. Role of myocardial revascularization in sudden cardiac
death. Circulation 1992;85 Suppl I:I112–7.
3. Rubin DA, Nieminski KE, Monteferrante JC. Ventricular arrhyth-
mias after coronary artery bypass surgery: incidence, risk factors, and
long-term prognosis. J Am Coll Cardiol 1985;6:307–10.
4. Costeas XF, Schoenfeld MH. Usefulness of electrophysiologic studies
for new-onset sustained ventricular tachyarrhythmias shortly after
coronary artery bypass grafting. Am J Cardiol 1993;72:1291–4.
5. Ducceschi V, D’Andrea A, Liccardo B, et al. Ventricular tachyarrhyth-
mias following coronary surgery. Int J Cardiol 2000;73:43–8.
6. Ferraris VA, Ferraris SP, Gilliam HS, Berry WR. Predictors of
postoperative ventricular dysrhythmias: a multivariate study. J Cardio-
vasc Surg 1992;32:12–20.
7. Kron IL, DiMarco JP, Harman KP. Unanticipated postoperative
ventricular tachyarrhythmias. Ann Thorac Surg 1984;38:317–22.
8. Ascione R, Caputo M, Calori G, et al. Predictors of atrial fibrillation
after conventional and beating heart coronary surgery: a prospective,
randomized study. Circulation 2000;102:1530–5.
9. Watters MPR, Ascione R, Ryder IG, et al. Hemodynamic changes
during beating heart coronary surgery with the ‘Bristol technique. ’ Eur
J Cardiothorac Surg 2001;19:34–40.
0. Steinberg JS, Gaur A, Sciacca R, Tan E. New-onset sustained ventricular
tachycardia after cardiac surgery. Circulation 1999;99:903–8.
1. Kaul TK, Fields BL, Riggins LS, et al. Ventricular arrhythmia
following successful myocardial revascularization: incidence, predic-
tors, and prevention. Eur J Cardiothorac Surg 1998;13:629–36.
2. Calafiore AM, Teodori G, Mezzetti A, et al. Intermittent antegrade
warm blood cardioplegia. Ann Thorac Surg 1995;59:398–402.
3. Guiraudon GM. Coronary artery bypass grafting in the management
of ventricular arrhythmias in patients with coronary artery disease.
Curr Opin Cardiol 1992;7:945–9.
4. Cheema AN, Sheu K, Parker M, et al. Nonsustained ventricular
tachycardia in the setting of acute myocardial infarction: tachycardia
characteristics and their prognostic implications. Circulation 1998;98:
2030–6.
5. Pires LA, Lehmann MH, Buxton AE, et al., the Multicenter Unsus-
tained Tachycardia Trial Investigators. Differences in inducibility and
prognosis of in-hospital versus out-of-hospital identified nonsustained
ventricular tachycardia in patients with coronary artery disease: clinical
and trial design implications. J Am Coll Cardiol 2001;38:1156–62.
6. Newby KH, Thompson T, Stebbins A, et al., the GUSTO Investi-
gators. Sustained ventricular arrhythmias in patients receiving throm-
bolytic therapy: incidence and outcome. Circulation 1998;98:2567–73.
7. Bigger T, Fleiss J, Kleiger R, et al. The relationship among ventricular
arrhythmias, left ventricular dysfunction, and mortality in the two
years after myocardial infarction. Circulation 1984;69:250–8.
8. Rahimtoola SH. From coronary artery disease to heart failure: role of
the hibernating myocardium. Am J Cardiol 1995;75:16E–22E.
9. Saxon LA, Weiner I, Stevenson WG. Monomorphic versus polymor-
phic ventricular tachycardia after coronary artery bypass grafting. Am J
Cardiol 1995;75:403–5.
0. Beauregard LA. Incidence and management of arrhythmias in women.
J Gend Specif Med 2002;5:38–48.
1. Pham TV, Rosen MR. Sex, hormones, and repolarization. Cardiovasc
Res 2002;53:740–51.2. Saba S, Zhu W, Aronovitzx MJ, et al. Effects of estrogen on cardiac
22
2
2
2
1638 Ascione et al. JACC Vol. 43, No. 9, 2004
Ventricular Arrhythmias During Coronary Surgery May 5, 2004:1630–8electrophysiology in female mice. J Cardiovasc Electrophysiol 2002;
13:276–80.
3. Aronson D, Burger AJ. The effect of sex on ventricular arrhythmic
event in patients with congestive heart failure. Pacing Clin Electro-
physiol 2000;25:1206–11.
4. The Amiodarone Trials Meta-Analysis Investigators. Effect of pro-
phylactic amiodarone on mortality after acute myocardial infarction
and in congestive heart failure; meta-analysis of individual data from
6500 patients in randomized trials. Lancet 1997;350:1417–24.5. Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival
in patients with ventricular fibrillation or symptomatic ventricular
tachycardia: the Antiarrhythmics Versus Implantable Defibrillators
(AVID) trial. J Am Coll Cardiol 1999;34:325–33.
6. Singh BN, Venkatesh N, Nademanee K, et al. The historical devel-
opment, cellular electrophysiology and pharmacology of amiodarone.
Prog Cardiovasc Dis 1989;31:249–80.
7. Elwood M. Critical Appraisal of Epidemiological Studies and Clinical
Trials. 2nd edition. Oxford: Oxford University Press, 1998.
